id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-283699-c4jjdj5o	Eslami, Gholamali	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	2020-08-19		.txt	text/plain	3476	188	51	With the national standard COVID-19 treatment protocol at the time being lopinavir/ritonavir 200/50 mg two tablets every 12 h plus hydroxychloroquine 400 mg daily, it was decided to conduct a two-arm trial where both arms would receive the standard protocol in addition to either ribavirin or sofosbuvir/ daclatasvir. In this open-label trial, the effects of sofosbuvir/daclatasvir and ribavirin in patients with severe COVID-19 were measured. The time required before observing clinical improvement was significantly less in patients treated with sofosbuvir/daclatasvir, and the side effects of the medication, such as GI bleeding and anaemia, were lower than in the group receiving ribavirin. In this open-label study, treatment of patients with severe COVID-19 with sofosbuvir/daclatasvir was significantly more effective than ribavirin through improved clinical symptoms, lower mortality rates, a shorter duration of both ICU and hospital stays, and fewer side effects.	./cache/cord-283699-c4jjdj5o.txt	./txt/cord-283699-c4jjdj5o.txt